IP Verse

Highly Sensitive Methods For Analysis Of Troponin - EP3168618

The patent EP3168618 was granted to Novilux on Nov 21, 2018. The application was originally filed on Apr 4, 2007 under application number EP16193284A. The patent is currently recorded with a legal status of "Revoked".

EP3168618

NOVILUX
Application Number
EP16193284A
Filing Date
Apr 4, 2007
Status
Revoked
Nov 1, 2024
Grant Date
Nov 21, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

MATHYS & SQUIREAug 21, 2019MATHYS & SQUIREADMISSIBLE

Patent Citations (64) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication Number
DESCRIPTIONUS20050048660
DESCRIPTIONWO1994US05468
DESCRIPTIONUS2005164317
DESCRIPTIONUS4168146
DESCRIPTIONUS4235601
DESCRIPTIONUS4366241
DESCRIPTIONUS4442204
DESCRIPTIONUS4979824
DESCRIPTIONUS5094594
DESCRIPTIONUS5208535
DESCRIPTIONUS5274240
DESCRIPTIONUS5480614
DESCRIPTIONUS5543838
DESCRIPTIONUS5571410
DESCRIPTIONUS5579687
DESCRIPTIONUS5603351
DESCRIPTIONUS5605662
DESCRIPTIONUS5645702
DESCRIPTIONUS5653859
DESCRIPTIONUS5653939
DESCRIPTIONUS5658413
DESCRIPTIONUS5681751
DESCRIPTIONUS5716825
DESCRIPTIONUS5730187
DESCRIPTIONUS5746901
DESCRIPTIONUS5755942
DESCRIPTIONUS5770029
DESCRIPTIONUS5858195
DESCRIPTIONUS5863801
DESCRIPTIONUS5955028
DESCRIPTIONUS5989402
DESCRIPTIONUS6033628
DESCRIPTIONUS6041515
DESCRIPTIONUS6071478
DESCRIPTIONUS6130101
DESCRIPTIONUS6132580
DESCRIPTIONUS6143152
DESCRIPTIONUS6355420
DESCRIPTIONUS6361671
DESCRIPTIONUS6386219
DESCRIPTIONUS6495104
DESCRIPTIONUS6533553
DESCRIPTIONUS6537437
DESCRIPTIONUS6554744
DESCRIPTIONUS6599436
DESCRIPTIONUS6606609
DESCRIPTIONUS6623613
DESCRIPTIONUS6689323
DESCRIPTIONUS6749734
DESCRIPTIONUS6783992
DESCRIPTIONUS6802342
DESCRIPTIONUS6811668
DESCRIPTIONUS6974305
DESCRIPTIONUS6974874
DESCRIPTIONUS6977305
DESCRIPTIONUS6991907
DESCRIPTIONWO9955461
OPPOSITIONEP2002260
OPPOSITIONEP2386858
OPPOSITIONUS2006078998
OPPOSITIONUS8343728
OPPOSITIONWO2005033283
OPPOSITIONWO2007114947
SEARCHWO2005033283

Non-Patent Literature (NPL) Citations (51) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference Text
DESCRIPTION- FEBS LETT., (1990), vol. 270, pages 57 - 61
DESCRIPTION- GENOMICS, (1994), vol. 21, pages 311 - 316
DESCRIPTION- J. IMMUNOL., (1992), vol. 149, pages 3914 - 3920
DESCRIPTION- KOERBIN ET AL., ANN CLIN BIOCHEM, (2005), vol. 42, pages 19 - 23
OPPOSITION- ALAN H B WU; NOELLE FUKUSHIMA; ROBERT PUSKAS; JOHN TODD; PHILIPPE GOIX, "Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single molecule) fluorescence detector", Oak Ridge Conference in San Jose, CA, (20060421), XP002526755
OPPOSITION- APPLE et al., "Plasma 99th Percentile Reference Limits for Cardiac Troponin and Creatine Kinase MB Mass for Use with European Society of Cardiology/American College of Cardiology Consensus Recommendations", CLINICAL CHEMISTRY, (20030000), vol. 49, no. 8, pages 1331 - 1336, XP055275580
OPPOSITION- FERGUSON et al., "Myocardial infarction redefined: the new ACC/ESC definition, based on cardiac troponin, increases the apparent incidence of infarction", Heart, (20020000), vol. 88, pages 343 - 347, XP055275577
OPPOSITION- MISSOV et al., "Circulating Cardiac Troponin I in Severe Congestive Heart Failure", Circulation, (19971100), vol. 96, pages 2953 - 2958, XP008002058
OPPOSITION- M.P VAN DIEIJEN-VISSER, "The sense of more sensitive troponin assays", Presentation, (20130000), pages 1 - 32, XP055275568
OPPOSITION- OHTANI et al., "Association between cardiac troponin T elevation and angioscopic morphology of culprit lesion in patients with non-ST-segment elevation acute coronary syndrome", American Heart Journal, (20050000), vol. 150, no. 2, pages 227 - 233, XP005008912
OPPOSITION- PANTEGHINI et al., "Evaluation of Imprecision for Cardiac Troponin Assays at Low-Range Concentrations", Clinical Chemistry, (20040000), vol. 50, no. 2, pages 327 - 332, XP055275579
OPPOSITION- UETTWILLER-GEIGER et al., "Multicenter Evaluation of an Automated Assay for Troponin I", Clinical Chemistry, (20020600), vol. 48, no. 6, pages 869 - 876, XP055341298
OPPOSITION- DE LEMOS et al., "Association of Troponin T Detected With a Highly Sensitive Assay and Cardiac Structure and Mortality Risk in the General Population", JAMA, (20101208), vol. 304, no. 22, pages 2503 - 2512, XP055059960
OPPOSITION- Alan H.B. Wu, "Introduction to Coronary Artery Disease (CAD) and Biochemical Markers", Alan H.B. Wu, Alan H.B. Wu, Cardiac Markers, Totowa, NJ, USA, Humana Press, (19980000), pages 2pp, 3 - 20, XP055275573
OPPOSITION- GAHLMANN et al., "Differential Expression of Slow and Fast Skeletal Muscle Troponin C", J Mol Biol, (19880000), vol. 201, pages 379 - 391, XP024009812
OPPOSITION- PHAM et al., "Prognostic value of low-level cardiac troponin-I elevations in patients without definite acute coronary syndromes", American Heart Journal, (20040000), vol. 148, no. 5, pages 776 - 782, XP004635871
OPPOSITION- FRANZINI et al., "The calculation of the cardiac troponin T 99th percentile of the reference population is affected by age, gender, and population selection: A multicentre study in Italy", Clinica Chimica Acta, (20150000), vol. 438, pages 376 - 381, XP029020403
OPPOSITION- CHRISTENSON et al., "Stratus@ CS cardiac troponin I method: performance characteristics including imprecision at low concentrations", Clinical Biochemistry, (20040000), vol. 37, pages 679 - 683, XP055275569
OPPOSITION- Mauro PANTEGHINI, "Role and importance of biochemical markers in clinical cardiology", European Heart Journal, (20040000), vol. 25, pages 1187 - 1196, XP055275663
OPPOSITION- JAFFE et al., "Biomarkers in Acute Cardiac Disease: The Present and the Future", Journal of the American College of Cardiology, (20060000), vol. 48, no. 1, pages 1 - 11, XP029650629
OPPOSITION- "Caposino and Kondratovich (2019) Considerations for Single-Measurement Risk- Stratification Strategies for Myocardial Infarction Using Cardiac Troponin Assays", Journal of the American College of Cardiology, vol. 74, no. 3, pages 283 - 284, XP085732932
OPPOSITION- VENGE et al., "Clinical Performance of Three Cardiac Troponin Assays in Patients With Unstable Coronary Artery Disease (a FRISC II Substudy", The American Journal of Cardiology, (20020501), vol. 89, pages 1035 - 1041, XP055275668
OPPOSITION- CARDINALE et al., "Left Ventricular Dysfunction Predicted by Early Troponin I Release After High-Dose Chemotherapy", Journal of the American College of Cardiology, (20000000), vol. 36, no. 2, pages 517 - 522, XP055275637
OPPOSITION- ALPERT et al., "Myocardial Infarction Redefined - A Consensus Document of The Joint European Society of Cardiology/ American College of Cardiology Committee for the Redefinition of Myocardial Infarction", Journal of the American College of Cardiology, (20000000), vol. 36, no. 3, pages 959 - 969, XP009099630
OPPOSITION- WALLACE et al., "Serum Troponins as Biomarkers of Drug-Induced Cardiac Toxicity", Current Issues; Toxicologic Pathology, (20040000), vol. 32, pages 106 - 121, XP055275627
OPPOSITION- Jillian R Tate; Et Al, "Reporting of Cardiac Troponin Concentrations", Clinical Chemistry, (20020000), vol. 48, no. 11, pages 2077 - 2080, XP055300111
OPPOSITION- ZELLER et al., "High Population Prevalence of Cardiac Troponin I Measured by a High-Sensitivity Assay and Cardiovascular Risk Estimation: the MORGAM Biomarker Project Scottish Cohort", European Heart Journal, (20140000), vol. 35, pages 271 - 281, XP055275648
OPPOSITION- ZETHELIUS et al., "Troponin I as a Predictor of Coronary Heart Disease and Mortality in 70-Year-Old Men: A Community-Based Cohort Study", Circulation, (20060000), vol. 113, pages 1071 - 1078, XP002399990
OPPOSITION- WALLACE et al., "Prevalence and Determinants of Troponin T Elevation in the General Population", Circulation, (20060000), vol. 113, pages 1958 - 1965, XP055275565
OPPOSITION- LYNGBAEK et al., "Risk stratification in stable coronary artery disease is possible at cardiac troponin levels below conventional detection and is improved by use of N-terminal pro-B-type natriuretic peptide", European Journal of Preventive Cardiology, (20130530), pages 1 - 11, XP055275657
OPPOSITION- KOERBIN et al., "The comparative analytical performance of four troponin I assays at low concentration", Ann Clin Biochem, (20050000), vol. 42, pages 19 - 23, XP055275660
OPPOSITION- TATE et al., "The determination of the 99th centile level for troponin assays in an Australian reference population", Ann of Clin Biochem, (20080000), vol. 45, pages 275 - 288, XP055275582
OPPOSITION- APPLE et al., "Prognostic Value of the Ortho Vitros Cardiac Troponin I Assay in Patients With Symptoms of Myocardial Ischemia", Am J Clin Pathol, (20030000), vol. 120, pages 114 - 120, XP002657936
OPPOSITION- MELANSON et al., "Earlier Detection of Myocardial Injury in a Preliminary Evaluation Using a New Troponin I Assay With Improved Sensitivity", Am J Clin Pathol, (20070000), vol. 128, pages 282 - 286, XP055275618
OPPOSITION- MORROW et al., "Evaluation of the AccuTnl Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes", Clinical Chemistry, (20030000), vol. 49, no. 8, pages 1396 - 1398, XP055300819
OPPOSITION- APPLE et al., "Validation of the 99th Percentile Cutoff Independent of Assay Imprecision (CV) for Cardiac Troponin Monitoring for Ruling Out Myocardial Infarction", Clinical Chemistry, (20050000), vol. 51, no. 11, pages 2198 - 2200, XP055300020
OPPOSITION- LAM et al., "Performance Evaluation and Subsequent Clinical Experience with the Abbott Automated Architect STAT Troponin-1 Assay", Clinical Chemistry, (20060100), vol. 52, no. 2, pages 298 - 300, XP055341301
OPPOSITION- SCHULZ et al., "Importance of Low Concentrations of Cardiac Troponins", Clinical Chemistry, (20060700), vol. 52, no. 8, pages 1614 - 1615, XP055275640
OPPOSITION- WU et al., "Development and Preliminary Clinical Validation of a High Sensitivity Assay for Cardiac Troponin Using a Capillary Flow (Single Molecule) Fluorescence Detector", Clinical Chemistry, (20060000), vol. 52, no. 11, pages 2157 - 2159, XP055041263
OPPOSITION- APPLE et al., "Cardiac Troponin Assays: Guide to Understanding Analytical Characteristics and Their Impact on Clinical Care", Clinical Chemistry, (20170000), vol. 63, no. 1, pages 73 - 81, XP055764504
OPPOSITION- Kavsak Peter A, Et Al, "Using the clinical chemistry score in the emergency department to detect adverse cardiac events: a diagnostic accuracy study", CMAJ OPEN, (20200101), vol. 8, no. 4, pages 676 - 684, XP055901205
SEARCH- ALAN H B WU ET AL, "Development and preliminary clinical validation of a high sensitivity assay for cardiac troponin using a capillary flow (single-molecule) fluorescence detector", INTERNET CITATION, (20060421), page 1, URL: http://www.singulex.com/documents/Singulex_Troponin_poster.pdf, (20090506), XP002526755 [XP] 1-10 * the whole document *
SEARCH- Alma M A Mingels, "High-sensitivity cardiac troponin assays", PhD thesis, University Maastricht, Maastricht, ISBN 978-9-46-159109-8, (20120203), pages 1 - 192, URL: http://arno.unimaas.nl/show.cgi?fid=24085, (20121015), XP055040983 [T] * the whole document *
SEARCH- DENISE UETTWILLER-GEIGER ET AL, "Multicenter Evaluation of an Automated Assay for Troponin I", CLINICAL CHEMISTRY., WASHINGTON, DC., (20020601), vol. 48, no. 6, ISSN 0009-9147, pages 869 - 876, XP055341298 [X] 5,8,9 * the whole document, in particular abstract; paragraph spanning pages 871 and 872; table 2 *
SEARCH- M PANTEGHINI ET AL., "Evaluation of Imprecision for Cardiac Troponin Assays at Low-range Concentrations", CLINICAL CHEMISTRY, (20040101), vol. 50, no. 2, pages 327 - 332, XP055275579 [A] 1-10 * the whole document, in particular abstract; paragraph spanning pages 330 and 331; table 3 *
SEARCH- CHRISTENSON ET AL., "Stratus CS cardiac troponin I method: performance characteristics including imprecision at low concentrations", CLINICAL BIOCHEMISTY, (20040101), vol. 37, no. 8, pages 679 - 683, XP055275569 [A] 1-10 * the whole document, in particular abstract *
SEARCH- THOMAS M A ET AL, "A review of troponin assay performance in Wales: can the same (method-dependent) decision limits be used in different sites?", ANNALS OF CLINICAL BIOCHEMISTRY, (20050901), vol. 42, no. 5, doi:10.1258/0004563054890006, ISSN 0004-5632, pages 351 - 356, XP009143610 [A] 1-10 * the whole document, in particular abstract; tables 1 and 2 *
SEARCH- FRED S APPLE ET AL, "Prognostic Value of the Ortho Vitros Cardiac Troponin I Assay in Patients With Symptoms of Myocardial Ischemia Risk Stratification Using European Society of Cardiology/American College of Cardiology Recommended Cutoff Values", AMERICAN JOURNAL OF CLINICAL PATHOLOGY, AMERICAN SOCIETY FOR CLINICAL PATHOLOGY, US, (20030701), vol. 120, no. 1, doi:10.1309/K1LKCLAM161RVY29, ISSN 0002-9173, pages 114 - 120, XP002657936 [A] 1-10 * the whole document, in particular abstract; page 115, paragraph spanning columns; page 119, column 1, last paragraph *
SEARCH- D. A. MORROW ET AL, "Evaluation of the AccuTnI Cardiac Troponin I Assay for Risk Assessment in Acute Coronary Syndromes", CLINICAL CHEMISTRY., WASHINGTON, DC., (20030801), vol. 49, no. 8, doi:10.1373/49.8.1396, ISSN 0009-9147, pages 1396 - 1398, XP055300819 [A] 1-10 * the whole document, in particular page 1396, column 2, lines 11-23 *
SEARCH- Q LAM ET AL, "Performance Evaluation and Subsequent Clinical Experience with the Abbott Automated Architect STAT Troponin-I Assay", CLINICAL CHEMISTRY, (200602), vol. 52, no. 2, pages 298 - 300, XP055341301 [X] 5,8,9 * the whole document, in particular abstract; page 299, paragraph spanning columns *
SEARCH- A. WU ET AL, "Development and Preliminary Clinical Validation of a High Sensitivity Assay for Cardiac Troponin Using a Capillary Flow (Single Molecule) Fluorescence Detector", CLINICAL CHEMISTRY, (20061101), vol. 52, no. 11, doi:10.1373/clinchem.2006.073163, ISSN 0009-9147, pages 2157 - 2159, XP055041263 [XP] 1-10 * the whole document, in particular page 2158, column 2, full paragraph; figure 1 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents